Post-transplant lymphoproliferative disorder after solid-organ transplant in children.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Seminars in Pediatric Surgery

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.sempedsurg.2017.07.002PMID 28964482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules

  2017cited by this paper
• Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis

  2017cited by this paper
• Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level

  2017cited by this paper
• Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

  2017cited by this paper
• The Role of Antiviral Prophylaxis for the Prevention of Epstein–Barr Virus–Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review

  2017cited by this paper
• Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients

  2017cited by this paper
• Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

  2017cited by this paper
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

  2017cited by this paper
• Checkpoint inhibitors in hematological malignancies

  2017cited by this paper
• Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

  2016cited by this paper
• The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.

  2016cited by this paper
• Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections

  2016cited by this paper
• Primary Epstein–Barr virus infection, seroconversion, and post‐transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study

  2016cited by this paper
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

  2016cited by this paper
• Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

  2016cited by this paper
• A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation.

  2016cited by this paper
• Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.

  2016cited by this paper
• Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

  2015cited by this paper
• The Biology and Clinical Utility of EBV Monitoring in Blood.

  2015cited by this paper
• Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series

  2015cited by this paper
• Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin

  2015cited by this paper
• First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis

  2014cited by this paper
• Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases

  2014cited by this paper
• Switching of EBV cycles between latent and lytic states

  2014cited by this paper
• Long-term outcomes of children after solid organ transplantation

  2014cited by this paper
• Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

  2014cited by this paper
• Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders.

  2014cited by this paper
• Adapted Treatment of Epstein–Barr Virus Infection to Prevent Posttransplant Lymphoproliferative Disorder After Heart Transplantation

  2014cited by this paper
• Seroprevalence of Epstein-Barr Virus Infection in U.S. Children Ages 6-19, 2003-2010

  2013cited by this paper
• Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.

  2013cited by this paper
• Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases

  2013cited by this paper
• Quality of life after organ transplantation in children

  2013cited by this paper
• Low-intensity therapy in adults with Burkitt's lymphoma.

  2013cited by this paper
• The World Health Organization Classification of Lymphoid Neoplasms

  2013cited by this paper
• Pretransplant Epstein-Barr virus serostatus and incidence of posttransplant lymphoproliferative disorder in pediatric renal transplants.

  2013cited by this paper
• Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

  2013cited by this paper
• Post‐transplant lymphoproliferative disorder: No relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients

  2013cited by this paper
• Post‐transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: Incidence, clinical features and outcome

  2013cited by this paper
• Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab

  2013cited by this paper
• Decreasing Incidence of Symptomatic Epstein‐Barr Virus Disease and Posttransplant Lymphoproliferative Disorder in Pediatric Liver Transplant Recipients: Report of the Studies of Pediatric Liver Transplantation Experience

  2013cited by this paper
• Low‐Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report

  2012cited by this paper
• T-cell therapy in the treatment of post-transplant lymphoproliferative disease

  2012cited by this paper
• Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

  2012cited by this paper
• Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

  2012cited by this paper
• Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.

  2012cited by this paper
• Strategy of pre-emptive management of Epstein-Barr virus post-transplant lymphoproliferative disorder after stem cell transplantation: results of European transplant centers survey

  2012cited by this paper
• A 16‐Year Multi‐Institutional Study of the Role of Age and EBV Status on PTLD Incidence Among Pediatric Heart Transplant Recipients

  2012cited by this paper
• Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

  2012cited by this paper
• PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis

  2012cited by this paper
• Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients.

  2011cited by this paper
• Outcomes in pediatric solid‐organ transplantation

  2011cited by this paper
• Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorder

  2011cited by this paper
• Radiotherapy is the best treatment method in post transplant lymphoproliferative disorders localizing in brain: a review of the literature.

  2011cited by this paper
• New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

  2011cited by this paper
• Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors.

  2010cited by this paper
• Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

  2010cited by this paper
• Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines

  2010cited by this paper
• Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines

  2010cited by this paper
• Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

  2010cited by this paper
• The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.

  2010cited by this paper
• Quality of life after pediatric solid organ transplantation.

  2010cited by this paper
• Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

  2010cited by this paper
• The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production

  2010cited by this paper
• Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression

  2009cited by this paper
• Post‐transplant lymphoproliferative disease in pediatric lung transplant recipients: Recent advances in monitoring

  2009cited by this paper
• Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

  2009cited by this paper
• Burkitt’s lymphoma variant of post-transplant lymphoproliferative disease (PTLD)

  2009cited by this paper
• Incidence of PTLD in Pediatric Renal Transplant Recipients Receiving Basiliximab, Calcineurin Inhibitor, Sirolimus and Steroids

  2008cited by this paper
• Epstein‐Barr virus load in whole blood is associated with immunosuppression, but not with post‐transplant lymphoproliferative disease in stable adult heart transplant patients

  2008cited by this paper
• Pediatric T‐cell post‐transplant lymphoproliferative disorder after solid organ transplantation

  2008cited by this paper
• Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

  2007cited by this paper
• CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.

  2007cited by this paper
• Human Herpesviruses: Reactivation and lytic replication of EBV

  2007cited by this paper
• Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

  2007cited by this paper
• Case–control study of risk factors for the development of post‐transplant lymphoproliferative disease in a pediatric heart transplant cohort *

  2007cited by this paper
• Reactivation and lytic replication of EBV

  2007cited by this paper
• Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab

  2007cited by this paper
• Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

  2006cited by this paper
• A case of fulminant post‐transplant lymphoproliferative disorder and septicemia

  2006cited by this paper
• Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival

  2006cited by this paper
• Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

  2006cited by this paper
• Treatment of PTLD with Rituximab or Chemotherapy

  2006cited by this paper
• Anthracycline-based Chemotherapy as First-line Treatment in Adults with Malignant Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation

  2006cited by this paper
• Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.

  2005cited by this paper
• Ganciclovir and Acyclovir Reduce the Risk of Post‐Transplant Lymphoproliferative Disorder in Renal Transplant Recipients

  2005cited by this paper
• Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.

  2005cited by this paper
• Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)

  2005cited by this paper
• Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression

  2005cited by this paper
• Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients

  2005cited by this paper
• Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

  2004cited by this paper
• Low-Dose Immunosuppression Reduces the Incidence of Post-transplant Lymphoproliferative Disease in Pediatric Liver Graft Recipients

  2004cited by this paper
• Hodgkin-like Post-transplant Lymphoproliferative Disorder in Children: Does It Differ from Post-transplant Hodgkin Lymphoma?

  2004cited by this paper
• Prompt versus preemptive intervention for EBV lymphoproliferative disease.

  2004cited by this paper
• Hodgkin's lymphoma after post‐transplant lymphoproliferative disease in a renal transplant recipient

  2004cited by this paper
• Complete immunosuppressive withdrawal as a uniform approach to post‐transplant lymphoproliferative disease in pediatric liver transplantation

  2004cited by this paper
• Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.

  2004cited by this paper
• Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry

  2004cited by this paper
• Establishment and Characterization of a Bank of Cytotoxic T Lymphocytes for Immunotherapy of Epstein-Barr Virus-Associated Diseases

  2004cited by this paper

• Subtype-specific progression of post-transplant lymphoproliferative disease (PTLD) in children: Implications for age-based surveillance and early intervention strategies.

  2025cites this paper
• Prognostic value of baseline 18F-FDG PET/CT metabolic parameters in post-transplant lymphoproliferative disorder after pediatric liver transplantation

  2025cites this paper
• The role of 18F-FDG PET/CT metabolic parameters in the differential diagnosis of post-transplant lymphoproliferative disorder after pediatric liver transplantation

  2024cites this paper
• Pediatric post‐transplant lymphoproliferative disorder: Do not overlook digestive involvement

  2023cites this paper
• Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

  2023cites this paper
• High-dimensional profiling of pediatric immune responses to solid organ transplantation

  2022cites this paper
• Indication for tonsillectomy in pediatric patients with suspected post-transplant lymphoproliferative disorder.

  2022cites this paper
• Current Practices on Diagnosis, Prevention and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Patients after Solid Organ Transplantation: Results of ERN TransplantChild Healthcare Working Group Survey

  2021cites this paper
• Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature.

  2021cites this paper
• Neoplasms of the Gastrointestinal Tract

  2021cites this paper
• Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective

  2021cites this paper
• Post-transplant Medication Challenges

  2021cites this paper
• Role of Histology Following Pediatric Liver Transplantation

  2021cites this paper
• Organ-Specific Issues of PTLD – Kidney

  2021cites this paper
• Identification of Peripheral Blood Cells Infected with Epstein–Barr Virus: A Practical Method for Choosing the Initial Treatment for Post-Transplantation Lymphoproliferative Disease

  2021cites this paper
• Post-transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation: A Population-based Study from Shiraz, Iran

  2021cites this paper
• Imaging Assessment of Complications from Transplantation from Pediatric to Adult Patients: Part 1: Solid Organ Transplantation.

  2020cites this paper
• A multicenter survey on post‐transplant lymphoproliferative disorders in pediatric heart transplant recipients: A case for development of consensus guidelines for screening, surveillance, and treatment?

  2020cites this paper
• Orgaandonatie bij kinderen – chirurgische technieken voor het uitnemen van de abdominale organen bij pediatrische donoren

  2019cites this paper
• Posttransplant Lymphoproliferative Disorder in Children: A 360-degree Perspective.

  2019cites this paper
• Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cites this paper
• Plasma Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an 18-Month-Old Heart Transplant Recipient: Case Report and Review of the Literature.

  2019cites this paper
• Transplantationsassoziierte lymphoproliferative Erkrankungen (PTLD) bei Kindern

  2018cites this paper
• Transplants for non-lethal conditions: a case against hand transplantation in minors

  2018cites this paper
• Post‐transplant lymphoproliferative disorder in pediatric intestinal transplant recipients: A literature review

  2018cites this paper
• Infections in pediatric solid-organ transplant recipients.

  2017cites this paper